Introduction
Cardiomyopathies are a heterogeneous group of disorders characterized by structural and functional abnormalities of the myocardium that are not explained solely by coronary artery disease or abnormal loading conditions. 1 These disorders represent a significant health burden since they can cause premature death from arrhythmia, progressive heart failure, or stroke. [2] [3] [4] [5] [6] [7] [8] [9] To date, most information about the presentation and natural history of cardiomyopathies has derived from cohort studies in a small number of specialized centres, and there is very little data describing the contemporary profile and the practical management of the patients outside highly expert units. The EURObservational Research Programme (EORP) Cardiomyopathy registry was conceived by the European Society of Cardiology (ESC) Working Group on Myocardial and Pericardial Disease, to collect clinical data on patients with a confirmed diagnosis of a cardiomyopathy ( Figure 1) . The general aim of the registry is to provide a summary of contemporary features and management of patients with cardiomyopathy or myocarditis, across a large range of centres in the Europe in order to improve clinical service provision and therapy.
In this article, we present the data on the adult population with a cardiomyopathy, combining Pilot and Long-Term phases. Enrollment of patients with a myocarditis or paediatric patients with a cardiomyopathy, is still ongoing.
Methods

General design
This is a prospective observational multinational multicentre registry of consecutive patients presenting to cardiology centres in the European countries. Participating centres were selected using pre-specified criteria (see Supplementary material online, File S1). Each centre was asked to enter about 40 consecutively-assessed patients (up to 40 in Pilot phase, minimum 40 in Long-Term phase) over a 12-month period. The study was approved by each local Ethical Committee according to the local rules. Written informed consent was obtained from all participants before data collection. All diagnostic or management procedures were left to the discretion of the attending physician, including the clinical investigations made at the time of enrollment, and diagnostic criteria were not centrally verified. Baseline data were collected (including demographic, clinical, cardiac, genetic, and therapeutic parameters) using a web-based electronic case report form. The EORP department of the ESC was responsible for study management, data quality control, and statistical analyses.
The registry was conducted by an Executive Committee and managed by the EORP department of the ESC. A Pilot phase of the registry, restricted to adult patients with a cardiomyopathy, was conducted for validating the structure and quality of the data set. 10 
Patients and cardiomyopathies subtypes
Patients with one of four major cardiomyopathy subtypes were eligible for the study: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM). Familial/genetic forms and nonfamilial/non-genetic forms were included. Patients met the following inclusion criteria for the adult cardiomyopathies registry: (i) age at enrollment >18 years, (ii) willing and able to give informed consent, (iii) able to comply with all study requirements, and (iv) documented cardiomyopathy fulfilling standard diagnostic criteria for probands or for relatives (see Supplementary material online, File S2). Relevant definitions used for analyses of subgroups (including definition of regions) are included in the Supplementary material online, File S3.
Statistical analyses
Univariable analysis was applied to both continuous and categorical variables. Continuous variables were reported as mean ± standard deviation 
Results
Enrollment
Sixty-nine centres from 18 countries participated in the study (Figure 2 , Supplementary material online, Table S1, Figure S1 ). A total of 3208 consecutive adult patients with a cardiomyopathy were enrolled ( 
Diagnosis
The commonest diagnosis was HCM (n = 1739, 54.2%), then DCM (n = 1260, 39.3%), ARVC (n = 143, 4.4%), and RCM (n = 66, 2.1%) ( Table 1) . In addition, left ventricular non-compaction was reported in 4.1% of total patients. Median age at diagnosis was 49.0 years (IQR 38-59) (Figure 3) , differed significantly between cardiomyopathies (P < 0.001) and was lower in patients with ARVC (39.0 years IQR 30-51) than in patients with RCM (54.0 years IQR 37-65). A large distribution for age at diagnosis was observed for all subtypes, with a 'lower extreme limit' of box-plot that was 0 years for HCM, 13 years for DCM, 15 years for RCM, and 2 years for ARVC.
Familial disease and aetiology
A history of familial disease was observed in 38.9% of the total population (Table 1) , with significant differences according to cardiomyopathy subtypes (P < 0.001). The proportion was higher in HCM and ARVC (48.5% and 40.6%, respectively) and lower in RCM and DCM (30.0% and 25.2%, respectively). Details concerning rare causes of cardiomyopathy subtypes are reported in Supplementary material online, Table S2 .
History of arrhythmia, symptoms, and diagnostic tests
Main symptoms, history of arrhythmia or stroke, and use of cardiac investigations are reported in Drugs and therapeutic procedures prior to enrollment 
Subgroups
Subgroup analyses are presented in Table 3 . Relatives when compared with probands were characterized by a lower median age at diagnosis (39.0 years, IQR 24-50, vs. 50.0 years, IQR 38-59, P < 0.001), they underwent cardiac investigations [electrocardiogram (ECG), echocardiogram, Holter-ECG, and MRI] in a similar or greater proportion and a defibrillator was implanted as frequently (25.6% vs. 25.0%).
Incident patients when compared with prevalent patients were characterized by a greater median age at diagnosis (51.0 years, IQR 40-60, vs. 47.0 years, IQR 35-57, P < 0.001), were more frequently probands (89.0% vs. 77.5%, P < 0.001), had a familial disease less frequently (28.7% vs. 45.7%, P < 0.001) and had a defibrillator implanted less frequently (16.7% vs. 33.6%, P < 0.001).
Patients of the Pilot phase, when compared with the Long-Term phase, were more frequently relatives (52.9% vs. 9 .7%, P < 0.001), had a familial disease more frequently (46.4% vs. 34.4%, P < 0.001), were more frequently diagnosed in the context of a family screening (16.1% vs. 9 .1%, P < 0.001), more frequently diagnosed with a rare underlying disease (6.2% vs. 3 .1%, P < 0.001) and were more frequently implanted with a defibrillator (28.3% vs. 24.7%, P = 0.023).
Considering the four main regions, patients from South area were most frequently relatives (25.0%, global comparison, P < 0.001), had a familial disease most frequently (49.4%, P < 0.001), were most frequently diagnosed in the context of a family screening (17.1%, P < 0.001) and more frequently diagnosed with a rare underlying disease (5.7%, P < 0.001). Patients from East area were less likely to undergo MRI and genetic testing but more had Holter-ECG. Patients from West area were more frequently implanted with a defibrillator (32.7%, P < 0.001).
Discussion
This is the first multinational European registry on cardiomyopathies. The analysis shows that the mode of presentation varies substantially between cardiomyopathy subtypes, and that all patients, whether probands or relatives, undergo multiple cardiac investigations and require substantial medical and device therapy. By providing realworld contemporary data on clinical characteristics and management, the registry provides a platform for the evaluation of guideline implementation across a range of different health care providers and organizations in the Europe and elsewhere.
Cardiomyopathy subtypes
As anticipated from previous studies, [3] [4] [5] [6] 11 HCM was the most frequent cardiomyopathy in the registry, followed by DCM, and then ARVC and RCM. The design of the registry did not allow us to estimate population prevalence of specific phenotypes, but it is notable that the ratio for DCM/HCM patients in this consecutive series was unexpectedly high, suggesting that the true prevalence of DCM could be higher than previously estimated and closer to the estimated prevalence of HCM. The study also shows the diversity and frequency of diagnostic tests that were performed, either for assessment of the cardiomyopathy, management of symptoms, or stratification of risk. This is illustrated by MRI, performed in nearly one-third of all patients, or by genetic testing, performed in more than one-third of patients. All these results emphasize the multidisciplinary approach and 
expertise that is required for the management of patients with a cardiomyopathy. 6, [12] [13] [14] [15] [16] [17] Arrhythmia burden
All cardiomyopathies increase the odds for life-threatening arrhythmias, but the degree to which they do so continues to raise controversy. [3] [4] [5] [6] [7] [8] [9] While recognizing that the patients enrolled in this series are necessarily selected, the frequency of malignant ventricular arrhythmia and atrial fibrillation was impressively high. This was paralleled by a high prevalence of prophylactic ICD implantation, [3] [4] [5] [6] [7] [8] 18, 19 ablation procedures, and pacemaker implantation. Importantly, the arrhythmic risk varied substantially between cardiomyopathy subtypes with ventricular arrhythmia or ICD implantation most frequently reported in ARVC and atrial fibrillation being the dominant rhythm issue in RCM. The fact that Holter-ECG and exercise test were performed in two-third or less of patients, even in incident patients where investigations are expected to be optimal, suggest a gap in cardiac investigations.
Familial forms and age at diagnosis
The registry emphasizes the high prevalence of inherited disease, with nearly 40% of the entire cohort reporting a familial disease, and the importance of referring relatives for evaluation since two-thirds of relatives were diagnosed through family screening. In addition, the burden of the disease in relatives was important since prevalence of symptoms and ICD implantation were as frequent as in probands.
The fact that the number of relatives in the registry was relatively low (less than one-fifth) suggests there is still a gap in family screening. 7, 8, 15, 16 In the total cohort of probands and relatives, the median age at diagnosis was relatively low, below, or equal to 50 years of age for all cardiomyopathies except RCM. [3] [4] [5] [6] Age at diagnosis was variable, in agreement with the known age-related penetrance of these diseases. Distribution of age at diagnosis was, however, unexpectedly wide with the 'extreme upper limit' beyond 70 years of age for all cardiomyopathy subtypes and the 'extreme lower limit' well below 10 years of age for HCM and ARVC. These results may suggest a modification of the recommendations about family screening in relatives, 7, 8, 15, 16 starting family screening earlier than the current threshold of 10 years of age and extending family screening or follow-up beyond the currently recommended age of 50-60 years.
From gaps to improvement of health care
The identification of potential gaps with existing recommendations is also supported by the heterogeneous management we observed between centres and between geographical areas. Important differences were especially observed between the Pilot phase, where centres were preselected because of a high level of expertise, and the Long-Term phase, were centres had a more variable level of expertise. This is illustrated by the high percentage of relatives in the Pilot phase, which probably reflects more developed family screening programs. The careful analysis of the Registry findings therefore suggests that some characteristics may be considered as potential markers of excellence in the context of quality evaluation of health services, particularly in the perspective of dedicated multidisciplinary heart teams that might be useful as shown in other areas. 20, 21 These indicators of expertise for a given centre may include the percentage of cardiac and extracardiac investigations performed in patients, the ratio of relatives vs. probands, the rate of patients with a rare cause, the median age at diagnosis of patients. Finally, differences we observed among the various geographic areas suggest that comparing the organization of health care systems for cardiomyopathies in the various countries may provide valuable insights that can be used for improvement of health care services in the Europe. Since recommendations or expert consensus for the management of the patients and families are available, 7, 8, [14] [15] [16] including about global management of arrhythmia and prevention of sudden cardiac death 22 , it can be hypothesized that variations in service provision are mostly related to economical or structural reasons. 
Limitations
Similar to registries in other fields, the voluntary nature of the enrolling centres, associated with their predefined characteristics, inevitably implies an uncertain representativeness of the enrolling network with respect to the Europe as a whole.
Conclusions
This is the first European registry focused on adult patients with the various cardiomyopathy subtypes (see Take home figure). It provides a unique picture of contemporary features and management of these patients. The results emphasize the complexity of services and multidisciplinary expertise required for the management of patients with a cardiomyopathy. The analysis of the results also identified potential gaps with existing recommendations. Work is warranted to understand the large variation in services provision as well as renewed efforts to provide evidence-based diagnostic processes and therapies.
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